MedTrace Logo

A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin

NCT05357911 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-11-21

No results posted yet for this study

Summary

AB-106-C111 is China-only study, for investigating the drug interaction between AB-106 and P-gp substrate (Digoxin). （n=16）

Conditions

Interventions

DRUG

AB-106, digoxin

Period 1, single dose of 0.25mg digoxin; Period 2, Coadministrate AB-106 600mg and 0.25mg digoxin

Sponsors & Collaborators

  • AnHeart Therapeutics Inc.

    collaborator INDUSTRY

  • Nuvation Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Shuangmiao Wang · AnHeart Therapeutics Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-13
Primary Completion
2021-08-20
Completion
2021-12-03

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05357911 on ClinicalTrials.gov